Cargando…

Prone versus Supine FDG PET/CT in the Staging of Breast Cancer

Supine [18F]Fluorodeoxyglucose (FDG) positron emission technology/computed tomography (PET/CT) is a commonly used modality for the initial staging of breast cancer, and several previous studies have shown superior sensitivity and specificity of prone FDG PET/CT in comparison to its supine counterpar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassar, Lara, Kassas, Mutaz, Abi-Ghanem, Alain S., El-Jebai, Malak, Al-Zakleet, Safaa, Baassiri, Amro S., Naccoul, Rami Abou, Barakat, Andrew, Tfayli, Arafat, Assi, Hazem, Berjawi, Ghina, Estrada-Lobato, Enrique, Giammarile, Francesco, Vinjamuri, Sobhan, Haidar, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914486/
https://www.ncbi.nlm.nih.gov/pubmed/36766472
http://dx.doi.org/10.3390/diagnostics13030367
_version_ 1784885680822812672
author Nassar, Lara
Kassas, Mutaz
Abi-Ghanem, Alain S.
El-Jebai, Malak
Al-Zakleet, Safaa
Baassiri, Amro S.
Naccoul, Rami Abou
Barakat, Andrew
Tfayli, Arafat
Assi, Hazem
Berjawi, Ghina
Estrada-Lobato, Enrique
Giammarile, Francesco
Vinjamuri, Sobhan
Haidar, Mohamad
author_facet Nassar, Lara
Kassas, Mutaz
Abi-Ghanem, Alain S.
El-Jebai, Malak
Al-Zakleet, Safaa
Baassiri, Amro S.
Naccoul, Rami Abou
Barakat, Andrew
Tfayli, Arafat
Assi, Hazem
Berjawi, Ghina
Estrada-Lobato, Enrique
Giammarile, Francesco
Vinjamuri, Sobhan
Haidar, Mohamad
author_sort Nassar, Lara
collection PubMed
description Supine [18F]Fluorodeoxyglucose (FDG) positron emission technology/computed tomography (PET/CT) is a commonly used modality for the initial staging of breast cancer, and several previous studies have shown superior sensitivity and specificity of prone FDG PET/CT in comparison to its supine counterpart. This retrospective study included 25 females with breast cancer referred for staging. They underwent supine FDG PET/CT followed by prone FDG PET/CT. The outcomes were: number of primary breast lesions, anatomical site of FDG-avid lymph nodes (LNs), and number and type of bone lesions, with SUVmax of all corresponding parameters. Performance was superior in prone acquisition compared to supine acquisition, with the respective results: 29 vs. 22 breast tumor lesions detected, 62 vs. 27 FDG-avid axillary LNs detected, sensitivity of 68% vs. 57%, specificity of 64% vs. 53%. The detection rate of axillary LNs in the prone position was significantly higher (p = 0.001). SUVmax for breast tumor lesions (p = 0.000) and number of detected axillary LNs (p = 0.002) were significantly higher in prone acquisition. Five patients were upstaged after experts read the prone acquisition. Prone FDG PET/CT acquisition is a promising technique in detecting primary breast lesions and metastatic LNs possibly missed in supine acquisition, which may lead to change in patient staging and management.
format Online
Article
Text
id pubmed-9914486
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99144862023-02-11 Prone versus Supine FDG PET/CT in the Staging of Breast Cancer Nassar, Lara Kassas, Mutaz Abi-Ghanem, Alain S. El-Jebai, Malak Al-Zakleet, Safaa Baassiri, Amro S. Naccoul, Rami Abou Barakat, Andrew Tfayli, Arafat Assi, Hazem Berjawi, Ghina Estrada-Lobato, Enrique Giammarile, Francesco Vinjamuri, Sobhan Haidar, Mohamad Diagnostics (Basel) Article Supine [18F]Fluorodeoxyglucose (FDG) positron emission technology/computed tomography (PET/CT) is a commonly used modality for the initial staging of breast cancer, and several previous studies have shown superior sensitivity and specificity of prone FDG PET/CT in comparison to its supine counterpart. This retrospective study included 25 females with breast cancer referred for staging. They underwent supine FDG PET/CT followed by prone FDG PET/CT. The outcomes were: number of primary breast lesions, anatomical site of FDG-avid lymph nodes (LNs), and number and type of bone lesions, with SUVmax of all corresponding parameters. Performance was superior in prone acquisition compared to supine acquisition, with the respective results: 29 vs. 22 breast tumor lesions detected, 62 vs. 27 FDG-avid axillary LNs detected, sensitivity of 68% vs. 57%, specificity of 64% vs. 53%. The detection rate of axillary LNs in the prone position was significantly higher (p = 0.001). SUVmax for breast tumor lesions (p = 0.000) and number of detected axillary LNs (p = 0.002) were significantly higher in prone acquisition. Five patients were upstaged after experts read the prone acquisition. Prone FDG PET/CT acquisition is a promising technique in detecting primary breast lesions and metastatic LNs possibly missed in supine acquisition, which may lead to change in patient staging and management. MDPI 2023-01-19 /pmc/articles/PMC9914486/ /pubmed/36766472 http://dx.doi.org/10.3390/diagnostics13030367 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nassar, Lara
Kassas, Mutaz
Abi-Ghanem, Alain S.
El-Jebai, Malak
Al-Zakleet, Safaa
Baassiri, Amro S.
Naccoul, Rami Abou
Barakat, Andrew
Tfayli, Arafat
Assi, Hazem
Berjawi, Ghina
Estrada-Lobato, Enrique
Giammarile, Francesco
Vinjamuri, Sobhan
Haidar, Mohamad
Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title_full Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title_fullStr Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title_full_unstemmed Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title_short Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
title_sort prone versus supine fdg pet/ct in the staging of breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914486/
https://www.ncbi.nlm.nih.gov/pubmed/36766472
http://dx.doi.org/10.3390/diagnostics13030367
work_keys_str_mv AT nassarlara proneversussupinefdgpetctinthestagingofbreastcancer
AT kassasmutaz proneversussupinefdgpetctinthestagingofbreastcancer
AT abighanemalains proneversussupinefdgpetctinthestagingofbreastcancer
AT eljebaimalak proneversussupinefdgpetctinthestagingofbreastcancer
AT alzakleetsafaa proneversussupinefdgpetctinthestagingofbreastcancer
AT baassiriamros proneversussupinefdgpetctinthestagingofbreastcancer
AT naccoulramiabou proneversussupinefdgpetctinthestagingofbreastcancer
AT barakatandrew proneversussupinefdgpetctinthestagingofbreastcancer
AT tfayliarafat proneversussupinefdgpetctinthestagingofbreastcancer
AT assihazem proneversussupinefdgpetctinthestagingofbreastcancer
AT berjawighina proneversussupinefdgpetctinthestagingofbreastcancer
AT estradalobatoenrique proneversussupinefdgpetctinthestagingofbreastcancer
AT giammarilefrancesco proneversussupinefdgpetctinthestagingofbreastcancer
AT vinjamurisobhan proneversussupinefdgpetctinthestagingofbreastcancer
AT haidarmohamad proneversussupinefdgpetctinthestagingofbreastcancer